The Research Council of Norway recently awarded grants to several innovation projects in the industrial sector. One of the lucky companies was the newcomer NordicRWE.
For six years we have hosted The Future of Cancer Treatment (Fremtidens kreftbehandling) with the same partners. What is this seminar series all about?
Dr. Bjørn Atle Bjørnbeth joined the board of Oslo Cancer Cluster during the annual general meeting.
Debattinnlegg: Innføring av nye legemidler for små pasientgrupper tar unødvendig lang tid. Noen blir ikke tatt i bruk i Norge i det hele tatt. Det er en utfordring, skriver artikkelforfatterne.
We want to highlight the fruitful collaborations in the cluster. In a new article series, we present members who have a cluster story to tell. This week, we meet LINK Medical.
Novartis joins the IMPRESS oncology study with six of its cancer medicines to treat up to one hundred patients.